Regulations.gov document
REF 2 - Drug Safety and Availability _ Notification re Letter from FDA CDER to Watson…
Supporting & Related Material · FDA-2019-N-3723 · posted Nov 1, 2019
Key facts
| Document ID | FDA-2019-N-3723-0004 |
|---|---|
| Title | REF 2 - Drug Safety and Availability _ Notification re Letter from FDA CDER to Watson Laboratories re Proposal to Withdraw Approval of an Abbreviated New Drug Application for Oxycodone Hydrochloride and Ibuprofen Tablets (ANDA 078394); Opportunity for a Hearing |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2019-N-3723 |
| Posted | Nov 1, 2019 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: